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Tuberculosis(TB) is one of the most neglected health problems and
has been out of control in many areas of the world. Since new
antituberculous alternatives, including controlled classical drug
delivery systems, are urgently needed to face this serious situation,
the purpose of the present work was the synthesis and
characterization of a prolonged action prodrug of isoniazid. The
N-methylene phosphonic chitosan (NMPC), a hydrosoluble
derivative of chitosan was used as drug carrier. This analog, as
well as its precursor, exhibits stimulatory activity on macrophages,
host cells of Mycobacterium tuberculosis. Due to its hydrosolubility,
it can be easily handled and intravenously administrated. The
NMPC can be obtained by reaction of chitosan with phosphorous
acid in presence of formaldehyde. Once synthesized, the coupling
with isoniazid was carried out after two steps: functionalization
of the drug with a succinic spacer group and activation of the
succinyl isoniazid through the cyclic analog 1-(pyridine-4-
carbonyl)-tetrahydro-pirydazin-3,6-dione.
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INTRODUCTION
Tuberculosis (TB) remains the leading cause of
death among the infectious diseases in the world. The
estimated 8.8 million new cases every year correspond to
52,000 deaths per week or more than 7,000 every day,
which translates into more than 1,000 new cases every
hour (Rattan, Kalia, Ahmad, 1998). Figure 1 shows the
epidemiological situation of tuberculosis in the world.
The resurgence of TB has been mainly attributed to
HIV epidemic. Also the frequent treatment interruptions by
patients due to the diminution of symptoms and drug
toxicity are responsible for recidives and, most importantly,
to the emergence of multidrug-resistant strains (Bloom,
Rook, 1994; Fätkenheuer et al., 1999).
From this perspective, the search for new
therapeutic alternatives to tuberculosis is of utmost
importance. One of the recommendations of World Health
Organization (1998) to tuberculosis treatment is the
strategy to achieve the patient’s compliance. This could be
possible either by using a most potent drug in a single dosis
or a drug that has prolonged action.
Molecular modification is one of the most promising
processes to introduce new drugs on the market. Prodrug
design is one of the processes comprehended by molecular
modification that deserves most attention (Ettmayer et al.,
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2004; Chung, Ferreira, 1999; Taylor, Kennewell, 1993).
Prodrug design involves a broad set of processes by
which an inactive transport form is produced. In vivo, by
means of enzymatic or chemical reactions (Wermuth,
2003), it releases the drug at the site of action or near it
(Bundgaard, 1985; Bundgaard, 1991). Figure 2 shows a
schematic representation of prodrug design.
A classical prodrug is employed with many
purposes, as to improve bioavailability, obtain prolonged
action, diminish toxicity, achieve high selectivity of action
and solve formulation problems.
According to Wermuth (2003) other two latent
forms may be basically obtained through this approach:
bioprecursors and targeted drugs, being the later usually
employed to obtain high level of selectivity.
The rational design of a prodrug must consider the
existence of moieties, in the drug and carrier, able to suffer
either specific biotransformation or non-selective one. A
FIGURE 2 - Representation of a prodrug design to enhance bioavailability.
FIGURE 1 - Epidemiological distribution of TB. Source: WHO, 2000.
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broad set of carriers may be chosen depending on the
objective of prodrug design (Chung, Ferreira, 1999).
Polymers are useful as drug carriers in order to
optimize drug delivery owing to their suitable
physicochemical and biological properties. Those carriers
are, frequently, used to prolong the action of drugs that must
be administered for a long period of time (Krogsgaard-
Larsen, Liljefors, Madsen, 1996; Schacht, Vansteenkiste,
Seymour,1996).
The polymers are either directly or through a spacer
covalently linked to the drug, that guarantee slow and gra-
dual release. Spacers are groups are those without biologic
activity that due to their strength and flexibility can be used
to facilitate the release of the drug. They also provide the
accessibility of enzymes to the linkage (Chung, Ferreira,
1999).
Polymer carriers can be natural or synthetic. Among
the natural polymers, polysaccharides, such as dextran,
have been widely used (Schacht, Vansteenkiste,
Seymour,1996). More recently, two polysaccharides have
deserved attention - chitin and chitosan (Muzzarelli,
Muzzarelli, 2002). Chitin is a widely available biopolymer
extracted from shrimp and crab shells, which is a
copolymer of β1→4-D-glucosamine and β1→4-N-acetyl-
D-glucosamine with variable composition. Chitosan, a
partially deacetylated form of chitin, contains free amine
groups, which can be used as sites for drug attachment
(Hirano et al., 1990).
A wide range of applications for chitosan includes
wastewater treatment, food, agriculture, cosmetic and
personal care, biotechnology and pharmaceutical areas.
Onishi et al. (1996) reported the use of chitosan as drug
carrier in the development of mitomycin C prodrugs.
Generally, chitosan is the most used carrier because
of the presence of free NH2 group that provides a
reactional center either to modification or drug linkage.
This derivative is almost atoxic (LD50 = 16 g.kg
-1 p.o. in
rats) and has immunopotentiating effect by stimulating
macrophages and increasing the humoral response
(Shibata, Metzger, Myrvik, 1997; Zang et al., 1995).
However, the aqueous solubility of chitosan depends on the
degree of protonation of the NH2 group by acid treatment,
which limits its versatility (Shigemasa et al., 1999). This is
particularly important in the case of chitosan with high
degree of deacetylation.
One reason for the difficulty in working with these
polymer lies in the rigid crystalline structure and in the
acetamide or primary amine group residues that have an
important role in the formation of conformational features
through intra and/or intermolecular hydrogen bonding
(Hirano et al., 1990).
Many efforts have been made to prepare water
soluble derivatives from chitosan (Zong et al., 2000).
Acylated (Kubota et al., 2000), sulphonated or sulphated
(Nishimura et al., 1998) derivatives have been synthesized
with good degrees of aqueous solubility.
Replacing the two hydrogens of the free amino
group by hydrophilic groups results in aqueous solubility
improvement. Based on this purpose, Heras et al. (2001)
suggested the synthesis of a new chitosan derivative – the
N-methylene phosphonic chitosan (NMPC) (Figure 3).
This compound showed an immediate solubility in
water, and in other aqueous systems as 1% NaOH and 1%
acetic acid.
According to the serious situation of TB and
considering the above described, our purpose was the
design and synthesis of a new macromolecular prodrug of
isoniazid (INH) with prolonged action. Isoniazid was
chosen since it is the most potent drug used in the current
therapeutics of TB. Also, it has been used as a
prophylactic agent, for six months, in tuberculin positive
individuals (Iseman, 1999). The N-methylene phosphonic
chitosan derivative was used to obtain a hydrosoluble
prodrug. Due to its immunostimulating macrophage
properties, we believe that the activity of such prodrug
against Mycobacterium tuberculosis could be enhanced
since they are the most infected cells in the host.
MATERIAL AND METHODS
Material
Chitosan was provided by Prof. Marconi Ginani from
Universidade Federal do Rio Grande do Norte, with
deacetylation degree of 80% estimated by infrared and
confirmed by Nuclear Magnetic Resonance (NMR).
Molecular weight of 1.8 x 105 was determined by
FIGURE 3 - N-methylene phosphonic chitosan mono and
disubstituted.
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measurements of viscosity in reometer and application of
Mark-Howink equation.
Isoniazid used was from FURP – Fundação para o
Remédio Popular, succinic anhydride from Merck,
phosphorous acid from Aldrich, thionyl chloride from Fluka
and dialysis tubing (cut off MW 12.000–14.000) from
Sigma. All other reagents (solvents and salts) of analytical
grade were from Merck.
Apparatus
The 1H NMR and 13C NMR spectrometry were
carried out on a NMR spectrometer Bruker ADPX,
300 MHz; chemical shifts are reported in ppm downfield
from internal or external TMS reference. The solvents
used were DMSO-d6, D2O and CDCl3. Acquisition was
obtained at 70 oC to all polymeric derivatives and at 25 oC
to other compounds. Infrared spectra were obtained in a
Bomem FTIR spectrophotometer, in KBr cells.
Lyophilization was performed on a Lamedid series a1-2
device, in case of polymers purified by dialysis.
General Synthetic Methods
The synthesis of the N-methylene phosphonic
derivative 1 was performed according to the literature
(Heras et al., 2001), as shown in Scheme 1.
One equivalent of phosphorous acid in water was
added dropwise to one equivalent (w/w) of 2% chitosan
solution in acetic acid with continuous stirring for 1 h. Then
the temperature of the reaction vessel was raised to 70 oC
and one part of 36.5%(w/w) formaldehyde was added
drop-wise over 1 h with reflux. Heating was protracted for
6 h at the same temperature. The clear pale yellow solution
was dialyzed against demineralized water for 48 h or until
the pH of water was raised to 6.8 in dialysis tubing with a
cut-off of 2 500 Da. Finally, the solution was frozen and
freeze-dried.
Succinyl isoniazid 2 was obtained from reaction of
succinic anhydride with isoniazid, in chloroform, at 70 oC for
4 hours, or in THF in ultrasound for 40 minutes (Scheme 2).
This compound was cyclized by reaction with thionyl
chloride at room temperature as showed in Scheme 3.
From this cyclisation, rings of five or six members
(compounds 3 or 3’ in the Scheme 3) could be obtained.
Prodrug 4 was, finally, obtained by reaction between
the cyclic derivative 3 (and/or 3’) (1 mmol) with the N-
methylene phosphonic chitosan (1) (1 mmol of free OH)
and 1 mmol of pyridine in N,N-dimethylformamide under
stirring at 90 oC for 30 hours (Scheme 4).
SCHEME 2 - Synthesis of succinyl isoniazid.
SCHEME 1 - Synthesis of N-methylene phosphonic derivative (NMPC).
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RESULTS AND DISCUSSION
Analytical data of 1-4 compounds are presented
bellow.
N-methylene phosphonic chitosan (1) – Following
the general procedure, 1.05 g (from 0.5 g of chitosan)** of
an amorphous pale yellow product was obtained. 1H-NMR
(300 MHz, D2O, ppm): 2.00 (3H, s, H10), 2,70 (2H, s,
H7(II*)), 3.40–3.66 (4H, m, H7(I*), H2(I), H2(II)), 4.31–
SCHEME 3 - Cyclisation of succinyl isoniazid.
SCHEME 4 - Synthesis of NMPC-INH prodrug.
4.58 (3H, m, H3–H6), 5.24 (1H, s, H1(I) ), 5.56 (1H, s,
H1(II) ), 6.43 (2H, s, H11), 8.51 (1H, s, H9).
I* = monosubstituted, II* = disubstituted; ** Since
the chitosan molecular weight could not be determined in
our laboratory, the yield in percentage was not calculated.
To standard chemical shifts see Shigemasa et al.
(1999) and Heras et al. (2001).
Succinyl Isoniazid (2) – By applying the procedure
early described, a white powder was obtained in good
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yields 92.4% (reflux in chloroform) and 80.99%
(ultrasound reaction).
1H-NMR (300 MHz, D2O, ppm): 2.70-2.78 (4H, m,
H11 and H12), 7.96 (2H, d, H3 and H5), 8.84 (2H, d, H2 and
H6). 
1H-NMR (300 MHz, DMSO, ppm): 7.78 (2H, d, H3
and H5 ), 8.77 (2H, d, H2 and H6 ), 10.06 (1H, s, H9), 10.66
(1H, s, H8), 11.74 (1H, s, H14). 
13C-NMR (75 MHz, D2O,
ppm): 28.05 and 28.66 (C11 and C12), 121.23 (C3 and
C5),139.42 (C4), 150.30 (C2 and C6), 163.82 (C7), 170.39
(C10), 173.44 (C13). IR (KBr, cm
-1): 3214 (νN-H), 1708
(νC=O acid),1608 (νC=O hydrazide and amide),1500
(νN-C=O), 1474–1411 (νC-N e HC=CH aromatic).
1-(pyridine-4-carbonyl)-tetrahydro-pirydazin-
3,6-dione (3): Stirring succinyl isoniazid with thionyl
chloride a white powder (72%) was obtained. 1H-NMR
(300 MHz, D2O, ppm): 2.80-2.95 (4H, m, H11 and H12),
8.39 (2H, d, H3 and H5), 9.03 (2H, d, H2 and H6).
1H-NMR(300 MHz, DMSO, ppm): 8.15 (2H, d, H3
and H5), 8.99 (2H, d, H2 and H6), 10.23 (1H, s, H9), 11.02
(1H, s, H1). 
13C-NMR(75 MHz, DMSO, ppm): 28.03 and
28.65 (C11 and C12), 123.56 (C3 and C5), 143.99 (C4),
145.83 (C2 and C6), 162.30 (C7), 170.28 (C10), 173.39
(C13). IR(KBr, cm
-1): 3179 (νN-H), 1727 (νC=O C10),
1605 (νC=O C7 and C13), 1513 – 1407 (νC-N and
HC=CH aromatic).
Chitosan-Isoniazid hemisuccinate (4) – The
potential prodrug was obtained as a pale brown solid
(0,021 g from 0,039 g of 1).  1H-NMR (300 MHz, D2O,
ppm): 1.98 (3H, s, H8), 2.70-2.80 (4H, m, H9, H10), 3.18-
3.66 (3H, m, H7, H2), 4.25–4.59 (3H, m, H3–H6), 5.26
(1H, s, H1(I)), 5.57 (1H, s, H1(II)), 8.46 (2H, d, H11 and
H14), 9.41 (2H, d, H12 and H13).
The N-methylene phosphonic derivative from
chitosan 1 was obtained in good yield (1.05 g) being,
immediately, soluble in water.
Chemical shifts at δ 5.24 and 5.56 were attributed to
H1 of monossacharidic ring, respectively, from chitosan
monosubstituted (I) and disubstituted (II) in NH2 moiety.
According to Heras et al. (2001), the yield of those
derivatives can be estimated by the rates between their
respective integrals (Table I).
Signs in δ 6.43 and 8.51 were attributed to amine and
amide hydrogens, respectively.
Succinyl isoniazid was obtained in 4 hours (92.4 %).
NMR and IR analyses of the acid (1708 cm-1, νC=O and
δ 173.44), from hydrazide and from amide groups
(1608 cm-1, νC=O and δ 163.82 and 170.39, respectively)
TABLE I - Rate between NMPC monosubstituted and disubstituted.
δ(ppm) Derivative Integral ΣH1 = 100% %
5.24 monosubstituted 0,6 0,9 66.67
5.56 disubstituted 0,3 33.33
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have initially confirmed its structure. The structure was
definetely confirmed by X-Ray spectrometry (Doriguetto
et al., 2003). The cyclic derivative was obtained just for
stirring the succinyl isoniazid with thionyl chloride for 9
hours. The purpose was to synthesize an acid chloride
which suffers cyclisation by nucleophilic attack of one of
the two nitrogens atoms from hydrazide moiety to carbonyl
group, producing the corresponding succinimide
hydrochloride. However, some questions have arisen from
1H and 13C NMR spectra analyses of compounds 2 and 3
(or 3’), due to their high structural similarity. Only slightly
differences in chemical shifts have been identified. This
could be observed because compound 3 was in its
respective hydrochloride salt form.
On the other hand, cyclisation could generate cycles
of five (3’) or six (3) members depending on which of the
two reactive nitrogens of succinyl hydrazide has been
involved in the nucleophilic attack (Scheme 3).
The infrared spectrum has suggested structural
differences between the compound 2 and the product of
the reaction with thionyl chloride. A band at 1708 cm-1 was
related to acid carbonyl stretching of succinyl isoniazid.
This band was not observed in the cyclic derivative, as a
band at 1727 cm-1 could be attributed to carbonyl group
stretching of cyclic moiety.
To prove that the cyclic derivative has been obtained,
the 2-D HMBC experiment with J2 at 5 Hz to the
compounds 2 and the compound 3 (or 3’) was performed
(Figure 4).
At first, the chemical shifts of the carbonyl groups of
the starting material were determined by 1H-NMR. The
hydrazide carbonyl group was identified with δ around 160.
This is in accordance with the reported value to isoniazid
(δ 160). The acid carbonyl group resonates at 170 ppm as
well as the amide carbonyl. But, the former has the most
deprotected carbonyl groups, and for this very reason, its
chemical shift is higher than the others.
The NMR spectrum obtained to succinyl isoniazid 2
showed that hydrogens from nitrogens 8 and 9 are coupling
with carbonyl carbons C7 and C10, respectively (Figure 4).
In addition, it was possible to identify the correlations
between the carbons C10 and C13, respectively, with the
hydrogens H11 and H12.
To the cyclic derivative, coupling between the
hydrogen H9 and the carbon C10 was detected (Figure 5).
The sign at 11.02 ppm is not coupling with any carbon on
spectrum. Thus, it was attributed to the hydrogen of the
hydrochloride form of pyridine ring.
The spectrum shows the presence of three different
carbonyl groups what could be possible in the formation of
FIGURE 4 - Compound 2 HMBC with J2 at 5 Hz.
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six-membered derivative which is an asymmetrical
structure (Figure 6). From the same reason, the obtention
of six-membered analog is confirmed by the presence of
two chemical shifts to the carbon C11 and C12 which should
be different if the six-membered analog had been obtained.
Finally, the prodrug was synthesized by reaction
between the NMPC with the cyclic derivative. A pale
yellow solid (0.021 g) readily soluble in water was
FIGURE 5 - Compound 3, HMBC with J2 at 5 Hz.
FIGURA 6 - Two possible derivatives obtained from
succinyl isoniazid cyclisation.
produced. The 1H-NMR spectrum has confirmed the
structure of the obtained product (H11 e H14, δ 8.46; H12
and H13 , δ 9.41).
This prodrug will be submitted to in vitro test in M.
tuberculosis culture.
RESUMO
Uso da N-metilenofosfonoquitosana para obter
pró-fármaco de isoniazida
Em 1993, a Organização Mundial de Saúde declarou
a tuberculose como emergência global, considerando-
se a gravidade do desenvolvimento mundial da doen-
ça. Face à necessidade de alternativas quimioterápicas
contra a tuberculose, especialmente em razão do apa-
recimento de formas multi-resistentes do
Mycobacterium tuberculosis, o objetivo do presente tra-
balho foi a síntese e caracterização de pró-fármaco de
ação prolongada de isoniazida. Para tanto, utilizou-
se como transportador derivado hidrossolúvel de
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quitosana-a N-metilenofosfonoquitosana (NMPC).
Este derivado, bem como seu precursor, exibe atividade
estimuladora de macrófagos, célula hospedeira do M.
tuberculosis. Por ser hidrossolúvel, este polímero é
manuseado mais facilmente e pode ser administrado
intravenosamente. O NMPC foi obtido da reação da
quitosana com ácido fosforoso em presença de
formaldeído. O acoplamento com a isoniazida foi re-
alizado em três etapas: funcionalização com um
espaçante succínico, ativação do produto
succinoilado por meio de endociclização, que resulta
na formação do análogo 1-(piridina-4-carbonil)-
tetraidropiridazin-3,6-diona, e o acoplamento com o
polímero propriamente dito.
UNITERMOS: Quitosana. N-metilenofosfonoquito-
sana. Isoniazida. Pró-fármacos.
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